Hui Gan
Scientist
Andrew Scott Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
In conjunction with leading the Phase I cancer clinical trials program at Austin Hospital, my main areas of responsibility involve management of patients with solid malignancies, with a particular focus on tumors of the head and neck, brain and genito-urinary tract. My research interests involve: • Phase 1/2 trials evaluating targeted novel biologic agents and small-molecule inhibitors, either alone or in conjunction with standard therapies. • Development of investigator-initiated clinical trials. I have developed or played a substantial role in the development of more than 6 trials. • Development and characterization of tumor-specific antibodies, particularly those targeting the EGFR and other members of the ErbB family.
Research Interest
Cancer clinical trials, tumors of the head and neck, brain and genito-urinary tract.
Publications
-
Perera, Rushika M., et al. "Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor–specific antibody generates enhanced antitumor activity." Clinical Cancer Research 11.17 (2005): 6390-6399.
-
Xiao, Li, et al. "The water-soluble fullerene derivative ‘Radical Sponge®’exerts cytoprotective action against UVA irradiation but not visible-light-catalyzed cytotoxicity in human skin keratinocytes." Bioorganic & medicinal chemistry letters 16.6 (2006): 1590-1595.
-
Loveland, Bruce E., et al. "Mannan-MUC1–pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma." Clinical Cancer Research 12.3 (2006): 869-877.
